Is there truly a risk of lymphoma from biologic therapies

摘要: The treatment of psoriasis has undergone a revolution with the advent biologic therapies, including infliximab, etanercept, adalimumab, efalizumab, and alefacept. Biologics are generally safe well tolerated. However, there been concern over risk lymphoma use these agents because their immunosuppressive properties. This review summarizes current evidence in regards to therapy obtained from case reports series, observational studies, clinical trials, meta-analyses. majority data for T-cell inhibitors comes relatively small, short-term trials. In addition published TNF-alpha have also studied extensively large cohort studies meta-analyses trials derived primarily rheumatoid arthritis population. Current neither sufficient completely rule out an increased associated biologics, nor firmly establish causal relationship between biologics lymphoma. Short- intermediate-term (e.g., up 4 years) appears be very respect risk, especially which potential risks appear defined. Continued vigilance is warranted; however, appropriate patient, risk-to-benefit profile highly favorable.